World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
61475
World Ranking
6380
National Ranking
3400

Overview

Mark S. Sulkowski is affiliated with the Johns Hopkins University School of Medicine in the United States. Their research primarily focuses on medicine, with a significant concentration in epidemiology, hepatology, and infectious diseases. Additional subfields include rheumatology and neurology, demonstrating a broad scope within medical sciences.

Their main topics of study include:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • HIV/AIDS drug development and treatment
  • HIV, Drug Use, Sexual Risk
  • Liver Disease and Transplantation
  • HIV/AIDS Research and Interventions

Sulkowski has contributed extensively to the scientific literature with over 315 publications in medicine. Prominent publication venues where they frequently publish include:

  • Journal of Hepatology
  • Clinical Infectious Diseases
  • The Journal of Infectious Diseases
  • UNC Libraries
  • Journal of Viral Hepatitis

Their notable recent papers are:

  • "Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review," 2020, UNC Libraries
  • "A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial," 2022, The Lancet. Gastroenterology & Hepatology
  • "Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19," 2022, JAMA
  • "Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis," 2021, Alcoholism Clinical and Experimental Research
  • "Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19," 2023, JAMA

Throughout their career, Sulkowski has collaborated frequently with several researchers, including:

  • Richard K. Sterling
  • Susanna Naggie
  • Oluwaseun Falade-Nwulia
  • Mandana Khalili
  • Michael Fried

The body of work by Mark S. Sulkowski reflects extensive engagement in infectious diseases and liver-related conditions, particularly hepatitis C and hepatitis B viruses, as well as broader HIV/AIDS research aspects. Their contributions span clinical trials, systematic reviews, and meta-analyses, focusing on treatment modalities and diagnostic advancements within their fields of study.

Best Publications

  • Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

    Richard K. Sterling;Eduardo Lissen;Eduardo Lissen;Nathan Clumeck;Ricard Sola

  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

    Dongliang Ge;Jacques Fellay;Alexander J. Thompson;Jason S. Simon

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

    Mark S. Sulkowski;David F. Gardiner;Maribel Rodriguez-Torres;K. Rajender Reddy

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

    John G. McHutchison;Gregory T. Everson;Stuart C. Gordon;Ira M. Jacobson

  • Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

    Mark S. Sulkowski;David L. Thomas;Richard E. Chaisson;Richard D. Moore

  • Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

    Shruti H. Mehta;Frederick L. Brancati;Mark S. Sulkowski;Steffanie A. Strathdee

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

    Kenneth K.E. Sherman;Steven S.L. Flamm;Nezam N.H. Afdhal;David Nelson

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

    Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  • Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

    Mark S. Sulkowski;David L. Thomas;David L. Thomas;Shruti H. Mehta;Richard E. Chaisson

  • Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review

    Oluwaseun Falade-Nwulia;Catalina Suarez-Cuervo;David R. Nelson;Michael W. Fried

  • Hepatitis C and progression of HIV disease.

    Mark S. Sulkowski;Richard D. Moore;Shruti H. Mehta;Richard E. Chaisson

  • Needlestick Injuries among Surgeons in Training

    Martin A. Makary;Ali Al-Attar;Christine G. Holzmueller;J. Bryan Sexton

  • Hepatitis C in the HIV-Infected Person

    Mark S. Sulkowski;David L. Thomas

  • Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

    David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich

Frequent Co-Authors

David L. Thomas
David L. Thomas Johns Hopkins University
Ira M. Jacobson
Ira M. Jacobson New York University
John G. McHutchison
John G. McHutchison Duke University
David R. Nelson
David R. Nelson University of Tennessee Health Science Center
Shruti H. Mehta
Shruti H. Mehta Johns Hopkins University
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Andrew J. Muir
Andrew J. Muir Duke University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Douglas T. Dieterich
Douglas T. Dieterich Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine but want to explore alternative pathways or expand your professional options, several online degree programs offer flexibility and diverse opportunities. Many students begin with fast track lpn programs, which allow for rapid entry into nursing while studying online.

For those interested in mental health, specialized psychiatric np programs provide advanced training and a focused career path. These programs are designed for registered nurses seeking to expand their expertise in psychiatric care.

Beyond direct patient care, the healthcare industry also offers roles in management and administration. An online health management degree is a smart option for students who want to lead healthcare teams or manage medical facilities.

If you’re pursuing advanced leadership roles, the cheapest online master degree in healthcare administration can help you build the skills to thrive in top positions without the high financial burden.

Best Scientists Citing Mark S. Sulkowski

Trending Scientists

Recently Published Articles